Time Course of the Blood Pressure Response to Oral Isradipine in Uncomplicated Mild-to-Moderate Essential Hypertension

Wp, Leary; Aj, Reyes; Maharaj, B; K, van der Byl

doi:10.1093/ajh/4.2.147s

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study we used non invasive ambulatory blood pressure monitoring to document the extent and duration of the antihypertensive effect of isradipine sustained release given once daily to essential hypertensives for 4 weeks. Several studies have shown that the antihypertensive effect of a given daily dose of isradipine, both in standard (Dahlof, 1989;Leary et al, 1991;Kirkendall, 1988) and SRO formulation (Carretta et al, 1992), is fully displayed within 4 weeks. We compared two drug regimens, i.e.…”

Section: Discussionmentioning

confidence: 99%

Evening vs morning isradipine sustained release in essential hypertension: a double‐blind study with 24 h ambulatory monitoring.

Fogari

Malacco

Tettamanti

et al. 1993

Brit J Clinical Pharma

View full text Add to dashboard Cite

A randomized, double-blind, placebo controlled study evaluated the effects on 24 h ambulatory blood pressure (ABP) of isradipine sustained release (I-SRO) administered once daily, in the morning (AM) or in the evening (PM Hg after AM and 14.3/7.9 mm Hg after PM intake. No significant differences were detected in the BP lowering effect of the two I-SRO regimens. In hypertensive patients, isradipine sustained release 5 mg once daily given in the morning or in the evening is effective in reducing the 24 h blood pressure profile, irrespective of the time of administration.

show abstract

Section: Discussionmentioning

confidence: 99%

Evening vs morning isradipine sustained release in essential hypertension: a double‐blind study with 24 h ambulatory monitoring.

Fogari

Malacco

Tettamanti

et al. 1993

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

Haemodynamics and tissue specificity with isradipine

Leslie

1993

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

The significant effects of isradipine in producing arterial vasodilatation and mild negative chronotropic effects without significant negative inotropic effects suggests that this agent should provide excellent antihypertensive efficacy in the treatment of perioperative hypertension. Isradipine may prove to be a safe antihypertensive treatment in patients with impaired ventricular function (cardiac failure), impaired myocardial perfusion (ischaemia), and in cases of selected conduction abnormalities or arrhythmias. The demonstration that its effects are limited to vascular resistance rather than vascular capacitance is an important distinguishing feature of isradipine compared with other antihypertensive agents. Finally, the potential application of this dihydropyridine calcium antagonist for cytoprotection and its effects on atherosclerosis remain exciting therapeutic prospects. K y words: Antihypertensive treatment; calcium antagonists; cardiovascular effects; isradipine; tissue-specific effects. 3 Curdiovasc Pharmacol 1991: 18 (suppl 3): S37-S40. 47. Rosenquist U, Ohman K P, Schenck H, et al. Antihypertensive and metabolic effect of isradipine in patients with hypertension and stable NIDDM. 3 Cardiovuc Pharmacol 1988: 12 (suppl 6): S 184. 48. Klauser R, Speiser P, Gisinger C, et al. Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type I1 diabetes mellitus. J Cardiovasc Pharmacol 1990: 15 (suppl 1): S93-S96.

show abstract

Time Course of the Blood Pressure Response to Oral Isradipine in Uncomplicated Mild-to-Moderate Essential Hypertension

Cited by 2 publications

References 0 publications

Evening vs morning isradipine sustained release in essential hypertension: a double‐blind study with 24 h ambulatory monitoring.

Evening vs morning isradipine sustained release in essential hypertension: a double‐blind study with 24 h ambulatory monitoring.

Haemodynamics and tissue specificity with isradipine

Contact Info

Product

Resources

About